- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| DOGWOOD THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.01. | Dogwood Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.01. | Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron Through Phase 2b Development | 122 | GlobeNewswire (Europe) | Pricing of $12.5 Million Registered Direct Offering & Concurrent Private Placement Offerings priced at-the-market under Nasdaq rules ALPHARETTA, Ga., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics... ► Artikel lesen | |
| 08.01. | Dogwood Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 22.12.25 | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain | 307 | GlobeNewswire (Europe) | - Halneuron- treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 - - The overall study dropout rate of ~4.4% is far below... ► Artikel lesen | |
| 02.12.25 | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Files New Synthetic Halneuron Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045 | 247 | ACCESS Newswire | - New Composition of Matter Intellectual Property ("IP") Filing Centered on First-in-Class, Fully Synthetically Manufactured Halneuron-- New Synthetic Process to be Used for Phase 3 Development Provides... ► Artikel lesen | |
| 28.11.25 | Dogwood Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.11.25 | Dogwood Therapeutics: Aktionäre machen Weg frei für Unternehmenszusammenschluss und neuen Eigenkapitalplan | 2 | Investing.com Deutsch | ||
| 21.11.25 | Dogwood Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.11.25 | Dogwood Therapeutics, Inc.: Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025 | 330 | ACCESS Newswire | - Continued low early termination rate among the first 80 study completers suggests Halneuron® and placebotreatmenthave been well tolerated ATLANTA, GEORGIA / ACCESS Newswire / November 11, 2025 / Dogwood... ► Artikel lesen | |
| 07.11.25 | Dogwood Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11.25 | Virios Therapeutics GAAP EPS of -$8.20 misses by $6.62 | 2 | Seeking Alpha | ||
| 06.11.25 | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Reports Third Quarter 2025 Financial Results | 361 | GlobeNewswire (Europe) | - Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron® Phase 2b trial, prespecified interim analysis remains on track for Q4 2025 release - - Secured... ► Artikel lesen | |
| 06.11.25 | Dogwood Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.10.25 | Dogwood Therapeutics, Inc.: Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 | 447 | ACCESS Newswire | ATLANTA, GA / ACCESS Newswire / October 30, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy... ► Artikel lesen | |
| 14.10.25 | Dogwood Therapeutics, Inc.: Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025 | 309 | ACCESS Newswire | ATLANTA, GA / ACCESS Newswire / October 14, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathic... ► Artikel lesen | |
| 09.10.25 | Dogwood Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.10.25 | Dogwood Therapeutics präsentiert Forschung zu Schmerzmittel Halneuron auf Fachkonferenz | 9 | Investing.com Deutsch | ||
| 07.10.25 | Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron Pain Research Program at the 19th Annual Pain Therapeutics Summit | 528 | ACCESS Newswire | ATLANTA, GEORGIA / ACCESS Newswire / October 7, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain, today... ► Artikel lesen | |
| 30.09.25 | Dogwood Therapeutics stock price target raised to $12 from $10 at H.C. Wainwright | 2 | Investing.com | ||
| 29.09.25 | Dogwood Therapeutics Stock Rallies 35% On Serpin Pharma Licensing Deal | 1 | RTTNews |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 93,15 | -0,16 % | Aufgrund von angeblichen Patentverletzungen zieht BioNTech gegen Moderna vor Gericht | Die Hersteller von Corona-Impfstoffen haben sich schon seit Jahren in den Haaren. Immer wieder gibt es Vorwürfe über Patentverletzungen. So auch in einem aktuellen Fall, bei dem BioNTech gegen den US-Hersteller... ► Artikel lesen | |
| EVOTEC | 5,720 | -2,36 % | Evotec: Das Biotech-Drama geht in die nächste Runde | Die Aktie des Hamburger Wirkstoffforschers Evotec versucht erneut den Befreiungsschlag, doch das Misstrauen am Markt ist greifbar. Nach einer beispiellosen Serie von Rückschlägen - von Management-Skandalen... ► Artikel lesen | |
| VALNEVA | 4,626 | -2,20 % | BioNTech, Valneva oder BB Biotech: Warum es HIER in Kürze knallt! | Die Biotechbranche steht zu Beginn des Jahres 2026 erneut im Spannungsfeld zwischen wissenschaftlicher Innovation und wachsender Skepsis der Kapitalmärkte. Nach Jahren extremer Kursbewegungen prüfen... ► Artikel lesen | |
| AMGEN | 329,00 | +0,14 % | Is Amgen Stock Outperforming the Dow? | ||
| NOVAVAX | 8,350 | -2,66 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| BIOGEN | 162,75 | +0,25 % | WONBIOGEN Co., Ltd: Won BioGen Accelerates Global Market Expansion with Advanced Moist Wound Care Technology | SEOUL, South Korea, Feb. 24, 2026 /PRNewswire/ -- Medical device manufacturer Won BioGen (CEO Kim Won-il) is accelerating its global market expansion based on its advanced moist wound care... ► Artikel lesen | |
| BIOFRONTERA | 2,780 | +3,73 % | PTA-Adhoc: Biofrontera AG: Erhöhung Prognose | DJ PTA-Adhoc: Biofrontera AG: Erhöhung Prognose
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR Schlagwort(e): Sonstiges
Biofrontera AG: Erhöhung Prognose
Leverkusen... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,385 | -1,53 % | BioNxt Solutions Inc.: BioNxt Announces Closing of Shares for Debt Settlement | VANCOUVER, BC / ACCESS Newswire / February 26, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that, further to its news release dated... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,100 | -5,51 % | Viking Therapeutics: The High-Stakes Weight Loss Contender | ||
| MAINZ BIOMED | 0,748 | +2,78 % | Mainz BioMed NV: Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples | ||
| INTELLIA THERAPEUTICS | 12,500 | +7,20 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027Process underway to reactivate global sites... ► Artikel lesen | |
| TEMPUS AI | 43,600 | -3,54 % | Tempus AI Quartalszahlen: 90 % Umsatzplus bestätigen KI-Trend in der Medizin | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das vierte Quartal 2025 veröffentlicht und ein rasantes Umsatzwachstum verzeichnet. Tempus AI -... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,394 | +4,23 % | Defence Therapeutics Inc.: Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March | Montreal, Quebec--(Newsfile Corp. - March 2, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology company advancing... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,272 | -1,86 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Full Year 2025 Financial Results and Provides Business Update | -Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A.... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,401 | -5,65 % | NurExone Biologic: Pionier in der Exosomen-Medizin! |
DOGWOOD THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,790 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DOGWOOD THERAPEUTICS INC finden Sie auf Wallstreet Online.